Premium
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference
Author(s) -
Munteanu M.,
Tiniakos D.,
Anstee Q.,
Charlotte F.,
Marchesini G.,
Bugianesi E.,
Trauner M.,
Romero Gomez M.,
Oliveira C.,
Day C.,
Dufour J.F.,
Bellentani S.,
Ngo Y.,
Traussnig S.,
Perazzo H.,
Deckmyn O.,
Bedossa P.,
Ratziu V.,
Poynard T.
Publication year - 2016
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.13770
Subject(s) - medicine , steatosis , gastroenterology , fatty liver , fibrosis , liver biopsy , grading (engineering) , steatohepatitis , biopsy , clinical endpoint , pathology , randomized controlled trial , disease , civil engineering , engineering
Summary Background Blood tests of liver injury are less well validated in non‐alcoholic fatty liver disease ( NAFLD ) than in patients with chronic viral hepatitis. Aims To improve the validation of three blood tests used in NAFLD patients, FibroTest for fibrosis staging, SteatoTest for steatosis grading and ActiTest for inflammation activity grading. Methods We pre‐included new NAFLD patients with biopsy and blood tests from a single‐centre cohort (FibroFrance) and from the multicentre FLIP consortium. Contemporaneous biopsies were blindly assessed using the new steatosis, activity and fibrosis ( SAF ) score, which provides a reliable and reproducible diagnosis and grading/staging of the three elementary features of NAFLD (steatosis, inflammatory activity) and fibrosis with reduced interobserver variability. We used nonbinary‐ ROC (NonBin AUROC ) as the main endpoint to prevent spectrum effect and multiple testing. Results A total of 600 patients with reliable tests and biopsies were included. The mean NonBin AUROC s (95% CI ) of tests were all significant ( P < 0.0001): 0.878 (0.864–0.892) for FibroTest and fibrosis stages, 0.846 (0.830–0.862) for ActiTest and activity grades, and 0.822 (0.804–0.840) for SteatoTest and steatosis grades. FibroTest had a higher NonBin AUROC than BARD (0.836; 0.820–0.852; P = 0.0001), FIB 4 (0.845; 0.829–0.861; P = 0.007) but not significantly different than the NAFLD score (0.866; 0.850–0.882; P = 0.26). FibroTest had a significant difference in median values between adjacent stage F2 and stage F1 contrarily to BARD , FIB 4 and NAFLD scores (Bonferroni test P < 0.05). Conclusions In patients with NAFLD , SteatoTest, ActiTest and FibroTest are non‐invasive tests that offer an alternative to biopsy, and they correlate with the simple grading/staging of the SAF scoring system across the three elementary features of NAFLD : steatosis, inflammatory activity and fibrosis.